| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.6 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.1 | 0.6 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.078 | 0.6 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.6 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |